Cost-effectiveness gatekeepers in England backed Novartis’ new heart failure drug Entresto, giving the drug more fuel for growth in Europe. The recommendation does come with restrictions, however, ...

Data from the TRANSITION study presented today at the European Society of Cardiology (ESC) Congress in Munich, Germany has shown that Entresto ® (sacubitril ...

Novartis AGNVS announced results from a post-hoc analysis from the PARADIGM-HF trial on cardiovascular drug Entresto. The results were published in JAMA Cardiology. The results demonstrated that ...

Novartis has held high hopes for cardiovascular med Entresto, pegging peak sales at $5 billion. Now, a major trial setback is hurting the drug's prospects, but Novartis is trying to looking at the ...

Update 3:48pm: Adds Novartis comment on appeal, updates shares. Novartis (NYSE:NVS) lost a patent ruling related to its blockbuster heart failure drug Entresto. Novartis ADRs fell 3.4%. A court found ...

Medicare Part D usually covers Entresto. However, the exact cost of Entresto can vary. In 2022, according to the most recent data, the annual out-of-pocket cost for Entresto for people with Medicare ...

Novartis AGNVS announced that its heart failure drug Entresto (previously known as LCZ696) has received FDA approval. Novartis stated that Entresto (twice-daily) is the first-in-class angiotensin ...

Fast growth for recently label-expanded drugs fuelled Novartis’ Q3 performance, despite headwinds from generic competition affecting more established blockbusters. Net sales for the Swiss big pharma ...